Deep Learning in the Detection and Prediction of Hydroxychloroquine Maculopathy

Launched by CENTRO HOSPITALAR DE LISBOA CENTRAL · Feb 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how advanced computer technology, called deep learning, can help detect and predict eye problems caused by long-term use of hydroxychloroquine, a medication often prescribed for conditions like lupus or rheumatoid arthritis. Many patients who take this medication may develop retinal toxicity, which can lead to vision problems. Early detection is crucial because it can help prevent serious damage to the eyes. The trial aims to automate the analysis of eye tests, making it easier and quicker to spot any issues.

To participate in this study, you need to be at least 65 years old and have been taking hydroxychloroquine for more than 10 years. Unfortunately, if you have other eye diseases that could confuse the results, you won't be eligible. If you join the trial, you will have your eye images collected through routine screenings, which will help researchers understand how to improve early detection of these eye problems. The study is currently recruiting participants, and it’s a great opportunity to contribute to important research that could benefit many patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with \> 10 years of HCQ intake
• Exclusion Criteria:
• • Patients with ocular diseases that might mimic HCQ maculopathy or interfer with HCQ maculopathy screening